Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries-Reference-Cited by-同舟云学术

Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries

Published:2012-01 Issue:1 Volume:104 Page:76-83
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Hoebert Joëlle M.,Mantel-Teeuwisse Aukje K.,van Dijk Liset,Bijlsma Johannes W.J.,Leufkens Hubert G.M.

Publisher

Elsevier BV

Subject

Health Policy

Reference28 articles.

1. Use of biologics in rheumatoid arthritis: where are we going?;Pucino;American Journal of Health-System Pharmacy,2006

2. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial;Goekoop-Ruiterman;Annals of Internal Medicine,2007

3. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, FIN-RACo trial group;Mottonen;Lancet,1999

4. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study;Verstappen;Annals of the Rheumatic Diseases,2009

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs;Smolen;Annals of the Rheumatic Diseases,2010

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Social, political, and economic determinants of access to biologics: A scoping review of structural determinants in the clinical disparities literature;Research in Social and Administrative Pharmacy;2022-12

2. The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor-α Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis;Journal of Rheumatic Diseases;2020-07-01

3. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage;JAMA Network Open;2019-12-06

4. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?;Frontiers in Pharmacology;2019-03-28

5. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis;Frontiers in Pharmacology;2018-09-20